Kazmi Syed Yousaf, Fathima Kauser, Khan Nazia, Kulsum Syeda Nazia, Faraz Ali
Basic Sciences, Majmaah University, AlMajmaah, SAU.
Pathology and Laboratory Medicine, Tumair General Hospital, Tumair, SAU.
Cureus. 2024 Feb 11;16(2):e53999. doi: 10.7759/cureus.53999. eCollection 2024 Feb.
Background Fosfomycin, nitrofurantoin, and co-trimoxazole are cheap and effective first-line oral antimicrobials in cases of uncomplicated cystitis in males and non-pregnant females. Fosfomycin and nitrofurantoin are called urinary antiseptics because these two drugs are primarily excreted in the kidney and concentrated in the urine without systemic effect. The present study was designed to evaluate the in vitro activities of fosfomycin, nitrofurantoin, and co-trimoxazole against uropathogens isolated at King Khalid Hospital Al-Majmaah, KSA. Methods The study was conducted at the King Khalid Hospital Al Majmaah, KSA, from September 1, 2021, until February 28, 2022. The patients' urine samples were inoculated on the Cystein Lactose Electrolytes Deficient (CLED) medium, and uropathogens were isolated. The organisms' identification and sensitivity testing against cotrimoxazole, fosfomycin, and nitrofurantoin was conducted using a Microscan automated analyzer, the MicroScan WalkAway Beckman Coulter, Sacramento, CA, USA. Results The study comprised non-repeat 137 patients who were either admitted to the hospital or treated as outpatients, yielding a total of 147 isolates. Nitrofurantoin showed a lower resistance rate, around 20% (n = 29), followed by fosfomycin at 23% (n = 34). The resistance rate of cotrimoxazole was 43% (n = 63). Overall, nitrofurantoin and fosfomycin showed relatively lower resistance against all isolates. Conclusions Being cheap and effective, we propose that fosfomycin and nitrofurantoin be used as first-line treatments in patients presenting with uncomplicated UTIs.
背景 磷霉素、呋喃妥因和复方新诺明是治疗男性和非孕女性单纯性膀胱炎的廉价且有效的一线口服抗菌药物。磷霉素和呋喃妥因被称为尿路防腐剂,因为这两种药物主要经肾脏排泄并在尿液中浓缩,无全身作用。本研究旨在评估磷霉素、呋喃妥因和复方新诺明对沙特阿拉伯王国哈立德国王阿尔马吉马医院分离出的尿路病原体的体外活性。方法 该研究于2021年9月1日至2022年2月28日在沙特阿拉伯王国哈立德国王阿尔马吉马医院进行。将患者的尿液样本接种在半胱氨酸乳糖电解质缺乏(CLED)培养基上,分离出尿路病原体。使用Microscan自动分析仪(美国加利福尼亚州萨克拉门托的MicroScan WalkAway Beckman Coulter)对分离出的病原体进行鉴定,并检测其对复方新诺明、磷霉素和呋喃妥因的敏感性。结果 该研究纳入了137例非重复住院或门诊患者,共分离出147株病原体。呋喃妥因的耐药率较低,约为20%(n = 29),其次是磷霉素,为23%(n = 34)。复方新诺明的耐药率为43%(n = 63)。总体而言,呋喃妥因和磷霉素对所有分离株的耐药性相对较低。结论 鉴于磷霉素和呋喃妥因廉价且有效,我们建议将其用作单纯性尿路感染患者的一线治疗药物。